Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Corbus Pharmaceuticals ( (CRBP) ) just unveiled an update.
On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company based in Norwood, Massachusetts, focusing on innovative scientific approaches to serious illnesses. Its pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody; and CRB-913 for obesity treatment.
YTD Price Performance: -21.26%
Average Trading Volume: 261,988
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $115.5M
For detailed information about CRBP stock, go to TipRanks’ Stock Analysis page.
